Navigation Links
Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs
Date:2/24/2009

PRINCETON, N.J., Feb. 24 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, has announced the appointment of Dr. Marcel Rozencweig as Senior Executive Vice President for Clinical Affairs. Prior to joining Sopherion, Dr. Rozencweig was a key Clinical Development Consultant to the Company and a member of the Sopherion Protocol Development Team for Myocet.

"I am excited to continue to contribute to the development of Myocet," said Dr. Rozencweig. "Myocet has the potential to be a valued addition to the first-line treatment regimen for metastatic breast cancer, particularly in patients with HER-2 overexpression."

Dr. Rozencweig was previously with GPC-Biotech since 2001. He has 18 years of experience with Bristol-Myers Squibb, where he held several senior leadership positions in drug development and strategic planning, including Vice President, Oncology, Infectious Diseases and Immunology Clinical Research; and Vice President, Strategic Planning and Portfolio Management.

"Dr. Rozencweig's world-renowned experience in oncology drug development is an ideal fit for Sopherion as we move Myocet forward," said Ronald H. Goldfarb, Ph.D., President and CEO of Sopherion Therapeutics. "His many achievements include significant contributions leading to the FDA approval of 11 drugs, mostly anticancer treatments, including the blockbusters Taxol(R) and Paraplatin(R) (carboplatin)."

Dr. Rozencweig is an Adjunct Associate Professor of Medicine at New York University and has authored or co-authored more than 200 scientific publications.

About Sopherion Therapeutics, LLC

Sopherion Therapeutics, LLC is a privately-held biotechnology company based in Princeton, New Jersey. The Company is focused on developing novel anti-cancer therapies for patients suffering with advanced cancer, particularly metastatic disease. Sopherion is dedicated to the acquisition, discovery, development and commercialization of novel anti-cancer therapies with unique therapeutic activities that address unmet medical needs in and extend human life. In 2004, Sopherion entered into an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc. for the future commercialization of Myocet in North America. For more information, visit www.sopherion.com.


'/>"/>
SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics to Resume Trading on MTA and NASDAQ
2. United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results
3. Cell Therapeutics Updates Shareholders on Trading
4. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
5. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
6. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
7. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
8. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
9. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
11. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... Attorney Robert “RC” Pate , founder of The Law ... Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric cancers. ... the effect of the critical funding gap for research into pediatric cancer research. From ...
(Date:1/19/2017)... ... 2017 , ... The CHP suggests that California drivers can avoid hydroplaning as ... and increasing the space between themselves and other vehicles, according to a January 3 ... R. Hassanlou notes that, rain or shine, drivers should always incorporate safe driving practices ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... ... January 19, 2017 , ... Infinity® Massage Chairs announced today ... implement new sales and marketing strategies. Grover comes with a total of 15 years ... a half years as Executive Vice President of Direct Sales at Traeger® Wood Pellet ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for ... people know that popular cosmetic fillers can enhance earlobes and rejuvenate ... director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Jan. 18, 2017  Kratom leaves, from a ... are often used to prepare tea-like beverages and ... million Americans annually to increase alertness, enhance well-being ... for minor aches and pains. PinneyAssociates, review of ... to assist FDA and DEA in determining the ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017  Hoy, ... lanzaron Access Accelerated, una iniciativa global para avanzar el ... y atención en países de renta baja y baja-media ... alcanzado un punto de crisis, particularmente en países de ... 80 por ciento de las muertes relacionadas con NCD. ...
Breaking Medicine Technology: